■ Nova Eye Medical said its minimally invasive glaucoma surgery (MIGS) device iTrack demonstrated a significant and stable reduction in IOP of more than 30% from baseline in both the iTrack-alone and iTrack+phaco groups at 24 months (total of 60 primary open-angle glaucoma eyes). In the iTrack-alone group, IOP decreased by 34% from 21.6±5.7 mmHg to 13.8±3.1mmHg. Patients in the iTrack+phaco group achieved a similar reduction in IOP, with mean IOP falling by 31% from 19.8±3.9 mmHg at baseline to 13.2±2.1 mmHg at the 24-month visit.

The reduction in number of medications was statistically significant in both groups at 24 months, decreasing from 3.0±0.7 to 2.1±1.3 in the iTrack-alone group, and from 2.5±1.1 to 1.3±1.2 in the iTrack+phaco group. Patients in the iTrack-alone group had a significantly higher baseline medication burden. The study, which encompassed all grades of glaucoma severity, was conducted by Mark Gallardo, MD, and the findings were published in Clinical Ophthalmology.